| Segment Reporting Disclosure [Text Block] |
In accordance with ASC 280, “Segment Reporting”, we define an operating segment as a business activity: (a) from which we may earn revenue and incur expenses; (2) whose operating results are regularly reviewed by the Chief Operating Officer (our Chief Operating Decision Maker) to make decisions about resources to be allocated to the segment and assess its performance; and (3) for which discrete financial information is available.
We currently have two reporting segments, Treatment and Services Segments, which are based on a service offering approach. This, however, excludes corporate headquarters, which do not generate revenue, our discontinued operations (see Note 9 – “Discontinued Operations”), and PF Medical S.A, a developmental entity whose primary purpose at this time is the R&D and marketing of medical isotope technology used in the medical diagnostic testing and is not generating any revenues (see Note 7 – “Perma-Fix Medical S.A.” for further information of this entity).
Our reporting segments are defined as below:
TREATMENT SEGMENT reporting includes:
|
|
-
|
nuclear, low-level radioactive, mixed, hazardous and non-hazardous waste treatment, processing and disposal services primarily through four uniquely licensed and permitted treatment and storage facilities; and
|
|
|
-
|
R&D activities to identify, develop and implement innovative waste processing techniques for problematic waste streams.
|
SERVICES SEGMENT, which includes:
|
|
-
|
On-site waste management services to commercial and government customers;
|
|
|
-
|
Technical services, which include:
|
|
|
o
|
professional radiological measurement and site survey of large government and commercial installations using advanced methods, technology and engineering;
|
|
|
o
|
integrated Occupational Safety and Health services including industrial hygiene (“IH”) assessments; hazardous materials surveys, e.g., exposure monitoring; lead and asbestos management/abatement oversight; indoor air quality evaluations; health risk and exposure assessments; health & safety plan/program development, compliance auditing and training services; and Occupational Safety and Health Administration (“OSHA”) citation assistance;
|
|
|
o
|
global technical services providing consulting, engineering, project management, waste management, environmental, and decontamination and decommissioning field, technical, and management personnel and services to commercial and government customers;
|
|
|
-
|
Nuclear services, which include:
|
|
|
o
|
technology-based services including engineering, decontamination and decommissioning (“D&D”), specialty services and construction, logistics, transportation, processing and disposal;
|
|
|
o
|
remediation of nuclear licensed and federal facilities and the remediation cleanup of nuclear legacy sites. Such services capability includes: project investigation; radiological engineering; partial and total plant D&D; facility decontamination, dismantling, demolition, and planning; site restoration; site construction; logistics; transportation; and emergency response; and
|
|
|
-
|
A company owned equipment calibration and maintenance laboratory that services, maintains, calibrates, and sources (i.e., rental) of health physics, IH and customized nuclear, environmental, and occupational safety and health (“NEOSH”) instrumentation.
|
The table below presents certain financial information of our operating segments as of and for the three months ended March 31, 2015 and 2014 (in thousands).
Segment Reporting as of and for the Quarter Ended March 31, 2015
|
|
|
Treatment
|
|
|
Services
|
|
|
Segments
Total
|
|
|
Corporate
And Other
|
|
(1)
|
Consolidated
Total
|
|
|
Revenue from external customers
|
|
$
|
9,749
|
|
|
$
|
3,851
|
|
|
$
|
13,600
|
|
|
$
|
—
|
|
|
$
|
13,600
|
|
|
Intercompany revenues
|
|
|
2
|
|
|
|
8
|
|
|
|
10
|
|
|
|
—
|
|
|
|
—
|
|
|
Gross profit
|
|
|
1,235
|
|
|
|
243
|
|
|
|
1,478
|
|
|
|
—
|
|
|
|
1,478
|
|
|
Interest income
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
8
|
|
|
|
8
|
|
|
Interest expense
|
|
|
(22
|
)
|
|
|
—
|
|
|
|
(22
|
)
|
|
|
(104
|
)
|
|
|
(126
|
)
|
|
Interest expense-financing fees
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(58
|
)
|
|
|
(58
|
)
|
|
Depreciation and amortization
|
|
|
764
|
|
|
|
190
|
|
|
|
954
|
|
|
|
12
|
|
|
|
966
|
|
|
Segment profit (loss), net of taxes
|
|
|
185
|
|
|
|
(303
|
)
|
|
|
(118
|
)
|
|
|
(1,896
|
)
|
|
|
(2,014
|
)
|
|
Expenditures for segment assets
|
|
|
104
|
|
|
|
16
|
|
|
|
120
|
|
|
|
1
|
|
|
|
121
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment Reporting as of and for the Quarter Ended March 31, 2014
|
|
|
Treatment
|
|
|
Services
|
|
|
Segments
Total
|
|
|
Corporate
And Other
|
|
(1)
|
Consolidated
Total
|
|
|
Revenue from external customers
|
|
$
|
7,673
|
|
|
$
|
2,871
|
|
|
$
|
10,544
|
|
|
$
|
—
|
|
|
$
|
10,544
|
|
|
Intercompany revenues
|
|
|
1
|
|
|
|
11
|
|
|
|
12
|
|
|
|
—
|
|
|
|
—
|
|
|
Gross profit (negative gross profit)
|
|
|
111
|
|
|
|
(17
|
)
|
|
|
94
|
|
|
|
—
|
|
|
|
94
|
|
|
Interest income
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
7
|
|
|
|
7
|
|
|
Interest expense
|
|
|
(10
|
)
|
|
|
—
|
|
|
|
(10
|
)
|
|
|
(143
|
)
|
|
|
(153
|
)
|
|
Interest expense-financing fees
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(45
|
)
|
|
|
(45
|
)
|
|
Depreciation and amortization
|
|
|
949
|
|
|
|
249
|
|
|
|
1,198
|
|
|
|
13
|
|
|
|
1,211
|
|
|
Segment loss, net of taxes
|
|
|
(1,174
|
)
|
|
|
(1,048
|
)
|
|
|
(2,222
|
)
|
|
|
(1,481
|
)
|
|
|
(3,703
|
)
|
|
Expenditures for segment assets
|
|
|
211
|
|
|
|
2
|
|
|
|
213
|
|
|
|
—
|
|
|
|
213
|
|
(1) Amounts reflect the activity for corporate headquarters (in both periods presented) and PF Medical S.A. (for quarter ended March 31, 2015 only), not included in the segment information.
|